Literature DB >> 8949640

Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease.

I Bjarnason1, R Batt, S Catt, A Macpherson, D Maxton, I S Menzies.   

Abstract

BACKGROUND/AIM: The reliability of a quantitative method for the non-invasive assessment of intestinal disaccharide hydrolysis was assessed.
METHODS: Differential excretion of intact disaccharide, expressed as ratios of lactulose to appropriate hydrolysable disaccharides in urine collected following combined ingestion, has been investigated in healthy volunteers with drug induced alpha-glucosidase inhibition, in subjects with primary hypolactasia, and patients with coeliac disease.
RESULTS: Oral administration of the alpha-glucosidase inhibitor 'Acarbose' (BAY g 5421, 200 mg) together with sucrose and lactulose increased the urinary sucrose/lactulose excretion ratios (% dose/10 h) fivefold. The effect was quantitatively reproducible, a higher dose of 'Acarbose' (500 mg) increasing the excretion ratio to about 1.0 indicating complete inhibition of intestinal sucrase activity. The suitability of the method for measuring differences in dose/response and duration of action was assessed by comparing three different alpha-glucosidase inhibitors (BAY g 5421, BAY m 1099, and BAY o 1248) and found to be satisfactory. Subjects with primary adult hypolactasia had urine lactose/lactulose excretion ratios raised to values indicating reduced rather than complete absence of lactase activity whereas sucrose/lactulose ratios were not significantly affected. 'Whole' intestinal disaccharidase activity assessed by this method demonstrated impairment of lactase, sucrase, and isomaltase in eight, one, and seven, respectively, of 20 patients with coeliac disease. By contrast in vitro assay of jejunal biopsy tissue indicated pan-disaccharidase deficiency in all but five of these patients. This shows the importance of distinguishing between 'local' and 'whole' intestinal performance.
CONCLUSIONS: Differential urinary excretion of ingested disaccharides provides a reliable, quantitative, and non-invasive technique for assessing profiles of intestinal disaccharidase activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8949640      PMCID: PMC1383342          DOI: 10.1136/gut.39.3.374

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  LACTOSURIA AND LACTASE DEFICIENCY IN ADULT CELIAC DISEASE.

Authors:  E WESER; M H SLEISENGER
Journal:  Gastroenterology       Date:  1965-05       Impact factor: 22.682

2.  Lactulose: a gas-liquid chromatography method of determination and evaluation of its use to assess intestinal mucosal damage.

Authors:  M Müller; J Walker-Smith; D H Shmerling; H C Curtius; A Prader
Journal:  Clin Chim Acta       Date:  1969-04       Impact factor: 3.786

3.  Quantitative estimation of sugars in blood and urine by paper chromatography using direct densitometry.

Authors:  I S Menzies
Journal:  J Chromatogr       Date:  1973-06-27

4.  A simple screening method for lactose malabsorption.

Authors:  M Isokoski; J Jussila; S Sarna
Journal:  Gastroenterology       Date:  1972-01       Impact factor: 22.682

5.  Determination of lactose intolerance by breath analysis.

Authors:  D H Calloway; E L Murphy; D Bauer
Journal:  Am J Dig Dis       Date:  1969-11

6.  The strip test for hypolactasia also works without ethanol.

Authors:  H Arola
Journal:  Scand J Gastroenterol       Date:  1988-09       Impact factor: 2.423

Review 7.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

8.  The effect of poorly absorbed solute on intestinal absorption.

Authors:  I S Menzies; A P Jenkins; E Heduan; S D Catt; M B Segal; B Creamer
Journal:  Scand J Gastroenterol       Date:  1990-12       Impact factor: 2.423

9.  Assessment of lactose absorption by measurement of urinary galactose.

Authors:  J D Grant; J A Bezerra; S H Thompson; R J Lemen; O Koldovsky; J N Udall
Journal:  Gastroenterology       Date:  1989-10       Impact factor: 22.682

10.  Combined assessment of intestinal disaccharidases in congenital asucrasia by differential urinary disaccharide excretion.

Authors:  D G Maxton; S D Catt; I S Menzies
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

View more
  5 in total

1.  Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence?

Authors:  J D Söderholm; G Olaison; E Lindberg; U Hannestad; A Vindels; C Tysk; G Järnerot; R Sjödahl
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

2.  Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability.

Authors:  K Borch; C Sjöstedt; U Hannestad; J D Söderholm; L Franzén; S Mårdh
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Brush border enzyme activities in the small intestine after long-term gliadin feeding in animal models of human coeliac disease.

Authors:  H Kozáková; R Stĕpánková; J Kolínská; M A Farré; D P Funda; L Tucková; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

4.  Use of the predictive sugars biomarker to evaluate self-reported total sugars intake in the Observing Protein and Energy Nutrition (OPEN) study.

Authors:  Natasa Tasevska; Douglas Midthune; Nancy Potischman; Amy F Subar; Amanda J Cross; Sheila A Bingham; Arthur Schatzkin; Victor Kipnis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-28       Impact factor: 4.254

5.  Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects.

Authors:  Mariko Nakamura; Sadako Nakamura; Tsuneyuki Oku
Journal:  Nutr Metab (Lond)       Date:  2009-07-14       Impact factor: 4.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.